Biomedical Research Education & Training
Faculty Member

Lindsley, Craig W., Ph.D.
Professor of Pharmacology
William K. Warren, Jr. Chair in Medicine

Lab Url:

Phone Number: (615) 322-8700

Email Address:

Lindsley, Craig's picture
Academic history
B.S., California State
Ph.D., UC Santa Barbara
Postdoc, Harvard University

Office Address   Mailing Address

12415 MRB IV

1205 Light Hall 37232-0697

Research Keywords
drug discovery, medicinal chemistry, organic sythesis, lead optimization, allosteric modulators,Cancer,Endocrinology,Neuroscience

Research Specialty
Medicinal chemistry efforts to validate novel targets/mechanisms

Research Description
The major focus of the Lindsley laboratory is drug discovery and medicinal chemistry. Students in my lab will collaborate with other members of the Pharmacology, Drug Metabolism and Clinical Pharmacology departments to pursue small molecule hits from high throughput screens, perform lead optimization studies to develop structure-activity-relationships (SAR) and ultimately deliver small molecules with acceptable properties to validate novel targets/mechanisms in in vivo animal models of target diseases. The molecular targets of interest are kinases, GPCRs, ion channels, nuclear hormone receptors and protein-protein interactions, with an emphasis on allosteric modulation as opposed to classical agonism/antagonism. Therapeutic areas of interest span cancer, neuroscience (schizophrenia, anxiety, pain, sleep, Parkinson's disease) and endocrinology (diabetes, obesity). Students will be exposed to every phase of classical drug discovery. As a member of ther Vanderbilt Institutue of Chemical Biology, training in my laboratory will be broad and involve organic synthesis, medicinal chemistry, pharmacology and drug metabolism. For many programs in the neuroscience area, students will have the opportunity to also develop radioligands for binding assay development and PET tracers for imaging studies.

Another focus in the group is parallel synthesis and the development of new technologies for library synthesis. The lab has state-of-the-art microwave synthesis technology, a mass-directed HPLC purification platform and a large collection of monomers and polymer-supported reagents. There are a number of projects directed at synthesizing libraries of small molecule protein-protein inhibitors, target family-directed libraries and other drug-like small molecule libraries for use in high throughput screening efforts.

The third area of interest in my group is synthetic organic chemistry. Students will have the opportunity to work on synthetic methodology projects as well as partial and total synthesis projects.

Ayala, JE, Chen, Y, Banko, JL, Sheffler, DJ, Williams, R, Telk, AN, Watson, NL, Xiang, Z, Zhang, Y, Jones, PJ, Lindsley, CW, Olive, MF, Conn, PJ. mGluR5 Positive Allosteric Modulators Facilitate both Hippocampal LTP and LTD and Enhance Spatial Learning. Neuropsychopharmacology, 2009

Bridges, TM, Marlo, JE, Niswender, CM, Jones, CK, Jadhav, SB, Gentry, PR, Plumley, HC, Weaver, CD, Conn, PJ, Lindsley, CW. Discovery of the First Highly M5-Preferring Muscarinic Acetylcholine Receptor Ligand, an M5 Positive Allosteric Modulator Derived from a Series of 5-Trifluoromethoxy N-Benzyl Isatins. J Med Chem, 2009

Conn, PJ, Christopoulos, A, Lindsley, CW. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov, 8(1), 41-54, 2009

Conn, PJ, Jones, CK, Lindsley, CW. Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. Trends Pharmacol Sci, 30(3), 148-55, 2009

Conn, PJ, Lindsley, CW, Jones, CK. Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends Pharmacol Sci, 30(1), 25-31, 2009

Delpire, E, Days, E, Lewis, LM, Mi, D, Kim, K, Lindsley, CW, Weaver, CD. Small-molecule screen identifies inhibitors of the neuronal K-Cl cotransporter KCC2. Proc Natl Acad Sci U S A, 106(13), 5383-8, 2009 PMCID:2654392

Engers, DW, Niswender, CM, Weaver, CD, Jadhav, S, Menon, UN, Zamorano, R, Conn, PJ, Lindsley, CW, Hopkins, CR. Synthesis and Evaluation of a Series of Heterobiarylamides That Are Centrally Penetrant Metabotropic Glutamate Receptor 4 (mGluR4) Positive Allosteric Modulators (PAMs). J Med Chem, 2009

Engers, DW, Rodriguez, AL, Williams, R, Hammond, AS, Venable, D, Oluwatola, O, Sulikowski, GA, Conn, PJ, Lindsley, CW. Synthesis, SAR and unanticipated pharmacological profiles of analogues of the mGluR5 ago-potentiator ADX-47273. ChemMedChem, 4(4), 505-11, 2009

Fadeyi, OO, Lindsley, CW. Rapid, general access to chiral beta-fluoroamines and beta,beta-difluoroamines via organocatalysis. Org Lett, 11(4), 943-6, 2009

Kennedy, JP, Conn, PJ, Lindsley, CW. A novel class of H3 antagonists derived from the natural product guided synthesis of unnatural analogs of the marine bromopyrrole alkaloid dispyrin. Bioorg Med Chem Lett, 19(12), 3204-8, 2009

Lavieri, R, Scott, SA, Lewis, JA, Selvy, PE, Armstrong, MD, Alex Brown, H, Lindsley, CW. Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part II. Identification of the 1,3,8-triazaspiro[4,5]decan-4-one privileged structure that engenders PLD2 selectivity. Bioorg Med Chem Lett, 19(8), 2240-3, 2009

Lewis, JA, Scott, SA, Lavieri, R, Buck, JR, Selvy, PE, Stoops, SL, Armstrong, MD, Brown, HA, Lindsley, CW. Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part I: Impact of alternative halogenated privileged structures for PLD1 specificity. Bioorg Med Chem Lett, 19(7), 1916-20, 2009

Lindsley, CW. Molecule of the month. FDA approves new treatment for fibromyalgia. Curr Top Med Chem, 9(2), 225, 2009

Marlo, JE, Niswender, CM, Days, EL, Bridges, TM, Xiang, Y, Rodriguez, AL, Shirey, JK, Brady, AE, Nalywajko, T, Luo, Q, Austin, CA, Williams, MB, Kim, K, Williams, R, Orton, D, Brown, HA, Lindsley, CW, Weaver, CD, Conn, PJ. Discovery and characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activity. Mol Pharmacol, 75(3), 577-88, 2009 PMCID:2684909

Miller, TW, P??rez-Torres, M, Narasanna, A, Guix, M, St?Yl, O, P??rez-Tenorio, G, Gonzalez-Angulo, AM, Hennessy, BT, Mills, GB, Kennedy, JP, Lindsley, CW, Arteaga, CL. Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. Cancer Res, 69(10), 4192-201, 2009 PMCID:2724871

Rodriguez, AL, Williams, R, Zhou, Y, Lindsley, SR, Le, U, Grier, MD, Weaver, CD, Conn, PJ, Lindsley, CW. Discovery and SAR of novel mGluR5 non-competitive antagonists not based on an MPEP chemotype. Bioorg Med Chem Lett, 19(12), 3209-13, 2009

Scott, SA, Selvy, PE, Buck, JR, Cho, HP, Criswell, TL, Thomas, AL, Armstrong, MD, Arteaga, CL, Lindsley, CW, Brown, HA. Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness. Nat Chem Biol, 5(2), 108-17, 2009

Sheffler, DJ, Williams, R, Bridges, TM, Xiang, Z, Kane, AS, Byun, NE, Jadhav, S, Mock, MM, Zheng, F, Lewis, LM, Jones, CK, Niswender, CM, Weaver, CD, Lindsley, CW, Conn, PJ. A Novel Selective Muscarinic Acetylcholine Receptor Subtype 1 (M1 mAChR) Antagonist Reduces Seizures Without Impairing Hippocampal-Dependent Learning. Mol Pharmacol, 2009 PMCID:2713127

Williams, R, Niswender, CM, Luo, Q, Le, U, Conn, PJ, Lindsley, CW. Positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4). Part II: Challenges in hit-to-lead. Bioorg Med Chem Lett, 19(3), 962-6, 2009

Brady, AE, Jones, CK, Bridges, TM, Kennedy, JP, Thompson, AD, Heiman, JU, Breininger, ML, Gentry, PR, Yin, H, Jadhav, SB, Shirey, JK, Conn, PJ, Lindsley, CW. Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in rats. J Pharmacol Exp Ther, 327(3), 941-53, 2008 PMCID:2745822

Bridges, TM, Brady, AE, Kennedy, JP, Daniels, RN, Miller, NR, Kim, K, Breininger, ML, Gentry, PR, Brogan, JT, Jones, CK, Conn, PJ, Lindsley, CW. Synthesis and SAR of analogues of the M1 allosteric agonist TBPB. Part I: Exploration of alternative benzyl and privileged structure moieties. Bioorg Med Chem Lett, 18(20), 5439-42, 2008

Bridges, TM, Lindsley, CW. G-Protein-Coupled Receptors: From Classical Modes of Modulation to Allosteric Mechanisms. ACS Chem Biol, 2008

Bridges, TM, Williams, R, Lindsley, CW. Design of potent GlyT1 inhibitors: in vitro and in vivo profiles. Curr Opin Mol Ther, 10(6), 591-601, 2008

Daniels, RN, Fadeyi, OO, Lindsley, CW. A new catalytic Cu(II)/sparteine oxidant system for beta,beta-phenolic couplings of styrenyl phenols: synthesis of carpanone and unnatural analogs. Org Lett, 10(18), 4097-100, 2008

J. Phillip Kennedy, John T. Brogan, Craig W. Lindsley. Progress toward the synthesis of piperazimycin A: exploration of the synthesis of γ-hydroxy and γ-chloropiperazic acids. Tetrahedron Letters, 49(26), 4116-4118, 2008

Jones, CK, Brady, AE, Davis, AA, Xiang, Z, Bubser, M, Tantawy, MN, Kane, AS, Bridges, TM, Kennedy, JP, Bradley, SR, Peterson, TE, Ansari, MS, Baldwin, RM, Kessler, RM, Deutch, AY, Lah, JJ, Levey, AI, Lindsley, CW, Conn, PJ. Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats. J Neurosci, 28(41), 10422-33, 2008 PMCID:2577155

Kennedy, JP, Brogan, JT, Lindsley, CW. Total synthesis and biological evaluation of the marine bromopyrrole alkaloid dispyrin: elucidation of discrete molecular targets with therapeutic potential. J Nat Prod, 71(10), 1783-6, 2008

Kennedy, JP, Williams, L, Bridges, TM, Daniels, RN, Weaver, D, Lindsley, CW. Application of combinatorial chemistry science on modern drug discovery. J Comb Chem, 10(3), 345-54, 2008

Kim, K, Miller, NR, Sulikowski, GA, Lindsley, CW. A new multi-gram synthetic route to labeling precursors for the D(2/3) PET agent 18F-fallypride. Bioorg Med Chem Lett, 18(16), 4467-9, 2008

Leslie N. Aldrich, Evan P. Lebois, L. Michelle Lewis, Natalia T. Nalywajko, Colleen M. Niswender, C. David Weaver, P. Jeffrey Conn, Craig W. Lindsley. MAOS protocols for the general synthesis and lead optimization of 3,6-disubstituted-[1,2,4]triazolo[4,3-b]pyridazines. Tetrahedron Letters , 50(2), 212-215, 2008

Lewis, JA, Daniels, RN, Lindsley, CW. Total synthesis of Ciliatamides A-C: stereochemical revision and the natural product-guided synthesis of unnatural analogs. Org Lett, 10(20), 4545-8, 2008

Lewis, JA, Lebois, EP, Lindsley, CW. Allosteric modulation of kinases and GPCRs: design principles and structural diversity. Curr Opin Chem Biol, 12(3), 269-80, 2008

Lewis, LM, Sheffler, D, Williams, R, Bridges, TM, Kennedy, JP, Brogan, JT, Mulder, MJ, Williams, L, Nalywajko, NT, Niswender, CM, Weaver, CD, Conn, PJ, Lindsley, CW. Synthesis and SAR of selective muscarinic acetylcholine receptor subtype 1 (M1 mAChR) antagonists. Bioorg Med Chem Lett, 18(3), 885-90, 2008 PMCID:2275053

Lindsley, CW. Tumor necrosis factor (TNF) blockers ignite FDA inquiry over cancer concerns. Curr Top Med Chem, 8(13), 1158, 2008

Lindsley, CW. Is Zetia a ''do nothing'' drug. Curr Top Med Chem, 8(5), 434, 2008

Lindsley, CW. Molecule of the month. The ''skinny'' on CB1 antagonists/inverse agonists: controversial obesity drugs will not go to FDA for approval. Curr Top Med Chem, 8(17), 1553, 2008

Lindsley, CW. Molecule of the month. Curr Top Med Chem, 8(12), 1100, 2008

Lindsley, CW, Barnett, SF, Layton, ME, Bilodeau, MT. The PI3K/Akt pathway: recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors. Curr Cancer Drug Targets, 8(1), 7-18, 2008

Miller, NR, Daniels, RN, Bridges, TM, Brady, AE, Conn, PJ, Lindsley, CW. Synthesis and SAR of analogs of the M1 allosteric agonist TBPB. Part II: Amides, sulfonamides and ureas--the effect of capping the distal basic piperidine nitrogen. Bioorg Med Chem Lett, 18(20), 5443-7, 2008

Niswender, CM, Johnson, KA, Weaver, CD, Jones, CK, Xiang, Z, Luo, Q, Rodriguez, AL, Marlo, JE, de Paulis, T, Thompson, AD, Days, EL, Nalywajko, T, Austin, CA, Williams, MB, Ayala, JE, Williams, R, Lindsley, CW, Conn, PJ. Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4. Mol Pharmacol, 74, 1345, 2008 PMCID:2574552

Niswender, CM, Lebois, EP, Luo, Q, Kim, K, Muchalski, H, Yin, H, Conn, PJ, Lindsley, CW. Positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4): Part I. Discovery of pyrazolo[3,4-d]pyrimidines as novel mGluR4 positive allosteric modulators. Bioorg Med Chem Lett, 18(20), 5626-30, 2008

R. Nathan Daniels, Kwangho Kim, Evan P. Lebois, Hubert Muchalski, Mary Hughes, Craig W. Lindsley. Microwave-assisted protocols for the expedited synthesis of pyrazolo[1,5-a] and [3,4-d]pyrimidines. Tetrahedron Letters, 49(2), 305-310, 2008

Sharma, S, Rodriguez, AL, Conn, PJ, Lindsley, CW. Synthesis and SAR of a mGluR5 allosteric partial antagonist lead: unexpected modulation of pharmacology with slight structural modifications to a 5-(phenylethynyl)pyrimidine scaffold. Bioorg Med Chem Lett, 18(14), 4098-101, 2008 PMCID:2533619

Shipe WD, Barrow JC, Yang ZQ, Lindsley CW, Yang FV, Schlegel KA, Shu Y, Rittle KE, Bock MG, Hartman GD, Tang C, Ballard JE, Kuo Y, Adarayan ED, Prueksaritanont T, Zrada MM, Uebele VN, Nuss CE, Connolly TM, Doran SM, Fox SV, Kraus RL, Marino MJ, Graufelds VK, Vargas HM, Bunting PB, Hasbun-Manning M, Evans RM, Koblan KS, Renger JJ. Design, synthesis, and evaluation of a novel 4-aminomethyl-4-fluoropiperidine as a T-type Ca2+ channel antagonist. J Med Chem, 51(13), 3692-5, 2008

Thomas, AL, Lindsley, CW. Molecule of the month. Overcoming resistance. Curr Top Med Chem, 8(1), 62, 2008

Yang ZQ, Barrow JC, Shipe WD, Schlegel KA, Shu Y, Yang FV, Lindsley CW, Rittle KE, Bock MG, Hartman GD, Uebele VN, Nuss CE, Fox SV, Kraus RL, Doran SM, Connolly TM, Tang C, Ballard JE, Kuo Y, Adarayan ED, Prueksaritanont T, Zrada MM, Marino MJ, Graufelds VK, DiLella AG, Reynolds IJ, Vargas HM, Bunting PB, Woltmann RF, Magee MM, Koblan KS, Renger J. Discovery of 1,4-substituted piperidines as potent and selective inhibitors of T-type calcium channels. J Med Chem, 51(20), 6471-7, 2008

Zeng Z, O'Brien JA, Lemaire W, O'Malley SS, Miller PJ, Zhao Z, Wallace MA, Raab C, Lindsley CW, Sur C, Williams DL Jr. A novel radioligand for glycine transporter 1: characterization and use in autoradiographic and in vivo brain occupancy studies. Nucl Med Biol, 35(3), 315-25, 2008

Zhao Z, Robinson RG, Barnett SF, Defeo-Jones D, Jones RE, Hartman GD, Huber HE, Duggan ME, Lindsley CW. Development of potent, allosteric dual Akt1 and Akt2 inhibitors with improved physical properties and cell activity. Bioorg Med Chem Lett, 18(1), 49-53, 2008

Zhao Z, Wolkenberg SE, Lu M, Munshi V, Moyer G, Feng M, Carella AV, Ecto LT, Gabryelski LJ, Lai MT, Prasad SG, Yan Y, McGaughey GB, Miller MD, Lindsley CW, Hartman GD, Vacca JP, Williams TM. Novel indole-3-sulfonamides as potent HIV non-nucleoside reverse transcriptase inhibitors (NNRTIs). Bioorg Med Chem Lett, 18(2), 554-9, 2008

Lindsley, C.W.; Weaver, D.; Conn, P.J.; Marnett, L.. Preclinical Drug Discovery Research and Training at Vanderbilt . ACS Chem. Bio., 2(1), 17-22, 2007

Daniels, R Nathan, Lindsley, Craig W. A new, non-SSRI mechanism of action for Prozac. Curr Top Med Chem, 7(10), 1039, 2007

Lindsley, CW, Weaver, D, Jones, C, Marnett, L, Conn, PJ. Preclinical drug discovery research and training at Vanderbilt. ACS Chem Biol, 2(1), 17-20, 2007

Lindsley, Craig W. Emerging from the shadow of Vioxx. Curr Top Med Chem, 7(7), 739, 2007

Lindsley, Craig W, Barnett, Stanley F, Yaroschak, Melissa, Bilodeau, Mark T, Layton, Mark E. Recent Progress in the Development of ATP-Competitive and Allosteric Akt Kinase Inhibitors. Curr Top Med Chem, 7(14), 1349-63, 2007

Pawluczyk, J.M.; McClain, R.T.; Denicola, C.; Mulhearn, J.J.; Rudd, D.J.; Lindsley, C.W. . Microwave-initiated living free radical polymerization: Optimization of the preparative scale synthesis of Rasta resins? . Tetrahedron Lett., 48, 1497-1501, 2007

Zhao, Z.; Wisnoski, D.D.; O?Brien, J.A.; Lemiare, W.; Williams, Jr., D.L.; Jacobson, M.A.; Wittman, M.; Ha, S.; Schaffhauser, H.; Sur, C.; Pettibone, D.J.; Duggan, M.E.; Conn, P.J.; Hartman, G.D.; Lindsley, C.W. . Challlenges in the development of mGluR5 positive allosteric modulators: the discovery of CPPHA . Bioorg. Med. Chem. Lett., 17, 1386-1390, 2007

Kausik,K.N.; Nolt, M.B.; Cato, M.J.; Kane, S.A.; Kiss, L.; Spencer, R.H.; Jixin Wang, J.; Lynch, J.L.; Regan, C.P.; Stump, G.L.; Li, B.;White, R.; Yeh, S.; Bogusky, M.J.; Bilodeau, M.T.; Dinsmore, C.J.; Lindsley, C.W.; Hartman, G.D.; Scott Wolkenberg S.E.;Trotter, B.W. . Potent antagonists of the atrial IKur/Kv1.5 potassium channel: synthesis and evaluation of analogous N,N- diisopropyl-2-(pyridine-3-yl)acetamides . Bioorg. Med. Chem.Lett. , 16, 5897-5861, 2006

Lindsley, C.W.; Shipe, W.D.; Wolkenberg, S.E.; Theberge, C.R.; Williams, D.L. Jr.; Sur, C.; Kinney, G.G. . Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia . Curr. Top. in Med. Chem., 6, 771-785, 2006

Lindsley, C.W.; Zhao, Z.; Leister, W.H.; OBrien, J.A.; Lemiare, W.; Williams, Jr., D.L.; Chen, T-B.; Chang, R.S.L.;Burno, M.; Jacobson, M.A.; Sur, C.; Kinney, G.G.; Pettibone, D.J.; Tiller,P.R.; Smith, S.;Tsou, N.N.; Duggan, M.E.; Conn, P.J.; Hartman, G.D. . Design, synthesis and in vivo efficacy of novel glycine transporter-1 (GlyT1) inhibitors derived from a series of [4-Phenyl-1-(propylsulfonyl)piperidin-4-yl] methyl benzamides . ChemMedChem, 1, 807-811, 2006

Lindsley, C.W.;Wolkenberg, S.E.; Kinney, G.G. . Progress in the preparation and testing of glycine transporter type-1 (GlyT1) inhibitors . Curr. Topics in Med. Chem., 8, 1883-1896, 2006

Nolt, M.B.; Smiley, M.A.; Varga, S.L.; McClain, R.T.; Wolkenberg, S.E.; Lindsley, C.W. . Convenient preparation of substituted 5-amino oxazoles via a microwave-assisted Cornforth rearrangement . Tetrahedron, 62(Tetrahedron Symposia-in-Print MAOS invited), 4698-4704, 2006

Shipe, W.D.; Yang, F.; Zhao, Z.; Wolkenberg, S.E.; Nolt, M.B.; Lindsley, C.W. . Convenient and general microwave-assisted protocols for the expedient synthesis of heterocycles . Heterocycles, 70, 665-689, 2006

Wolkenberg, S.E.; Zhao, Z.; Kapitskaya, M.; Webber, A.L.; Pertukhin, K.; Tang, Y.S.; Dean, D.C.; Hartman, George D.; Lindsley, C.W. . Identification of potent agonists of Photoreceptor-Specific Nuclear Receptor (NR2E3) and preparation of a radioligand . Bioorg. Med. Chem. Lett., 16, 5001-5004, 2006

Defeo-Jones, D.; Barnett, S.F.; Fu, S.; Hancock, P.J.; Haskell, K.M.; Leander, K.R.; McAvoy, E.; Robinson, R.G.; Duggan, M.E.; Lindsley, C.W.; Zhao, Z.; Huber, H.E.; Jones, R.E. . Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members . , 4, 271-278, 2005

Kim, D.; Cheng, G.Z.; Lindsley, C.W.; Yang, H.; Cheng, J.Q. . The Akt/PKB pathway: molecular target for cancer therapy . Oncogene, 24, 7482-7492, 2005

Kinney, G.G.; O?Brien, Lemaire, W.; Burno, M.? Bickel, D.J.; Clements, M.K.; Wisnoski, D.D.; Lindsley, C.W.; Tiller, P.R.; Smith, S.; Jacobson, M.A.; Sur, C.; Duggan, M.E.; Pettibone, D.J.; Williams, Jr., D.W. . A novel selective allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5) has an antipsychotic profile in rat behavioral models . J. Pharmacol. Exp. , 313, 199-211, 2005

Lindsley, C.W.; Bogusky, M.J.; Leister, W.H.; McClain, R.T.; Robinson, R.; Barnett, S.F.; Defeo-Jones, D.; III Ross, C.W.; Hartman, G.D. . Synthesis and biological evaluation of unnatural canthine alkaloids . Tetrahedron Lett., 46, 2779-2782, 2005

Lindsley, C.W.; Zhao, Z.; Leister, W.H.; Robinson, R.G.; Barnett, S.F.; Defeo-Jones, D.; Jones, R.E.; Hartman, G.D.; Huff, J.R.; Huber, H.E.; Duggan, M.E. . Allosteric Akt (PKB) kinase inhibitors. Discovery and SAR of isozyme selective inhibitors . Bioorg. Med. Chem. Lett., 15, 761-764, 2005

Lindsley, C.W.; Wisnoski, D.D.; Leister, W.H.;; O'Brien, J.A.; Lemiare, W.; Williams, Jr., D.L.; Burno, M.; Sur, C.; Kinney, G.G.; Pettibone, D.J.; iller, P.R.; Smith, S.; Duggan, M.E .; Hartman, G.D.; Conn, P.J.; Huff, J.R. . Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N-(1,3-Diphenyl-1H-pyrazol-5-yl)benzamides that potentiate receptor function in vivo . J. Med.Chem., 47, 5825-5828, 2004

Postdoctoral Position Available

Postdoctoral Position Details
Postdoc position available - drug discovery/lead optimization. Develop small molecule screening leads into proof of concept compounds to validate new targets/mechanisms in animal models. Work closely with colleagues in pharmacology. Some organic chemistry experience is required.

Updated Date